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Might your respiratory patient have alpha-1 antitrypsin deﬁciency?As the journal that focuses on the care of patients with chronic
pulmonary disorders we want to enlist Heart & Lung readers in
addressing an important problem.
In the primary care setting, it is important to screen adult
patients with asthma and COPD for alpha-1 antitrypsin
deﬁciency (AATD)
AATD is one of the most common hereditary diseases in the
world, with a higher prevalence than cystic ﬁbrosis. However, AATD
is underdiagnosed and under-recognized,1,2 partly as a result of
misconceptions about the proﬁle of a ‘typical’ AATD patient. AATD
has no unique symptoms so clinicians don’t often look to see if
AATD might be the underlying cause for the chronic obstructive
pulmonary disease (COPD) or asthma symptoms their patients
experience. Without appropriate treatment, AATD can have a poor
prognosis due to the ongoing accelerated deterioration of lung
tissue, leading to lung transplantation or death. The time between
the onset of respiratory symptoms and diagnosis of AATD has been
estimated at 7.2 years for individuals with severe deﬁciency, with
individuals havingmultiple primary care and specialist visits before
obtaining the correct diagnosis.3 Therefore, there is an urgent need
for both early and accurate diagnosis of AATD so appropriate
management can be put in place to slow disease progression and
limit irreversible lung damage.
AATD is a monogenic hereditary disorder that increases the
risk of lung and liver disease
Patients with AATD carry mutation(s) in the SERPINA1 gene,
leading to low levels or decreased function of the proteinase in-
hibitor alpha-1 antitrypsin (also known as, alpha-1 proteinase in-
hibitor, A1-PI). The most common alleles include M (normal allele),
Z (associated with severe AATD), and S (associated with mild
AATD). In healthy individuals, the liver produces A1-PI at levels
required to protect lungs and other tissues from the activity of
neutrophil elastase (NE). NE is a serine proteinase that plays a
major role in various aspects of inﬂammation and when left un-
checked, degrades elastin in connective tissues.4 In people with
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with AATD include diseases of the liver, skin, and vasculature.6
Triggers for testing include the diagnosis of COPD, abnormal
spirometry, family history of lung or liver disease, or asthma
in an adult that is only partially responsive to medical therapy
AATD may be suspected through either abnormal spirometry
test results suggesting irreversible airway obstruction, or through
known family medical history. The American Thoracic Society
(ATS)/European Respiratory Society (ERS) statement recommends
testing be carried out in individuals with emphysema, COPD or
asthma with incompletely reversible airﬂow obstruction, and
individuals with ‘evidence of lung disease and smoking or occu-
pational exposure’.6 Similarly, individuals with a late onset of
asthma-like symptoms should be tested (Table 1).6e8When AATD is
suspected, an inexpensive blood test can assess A1-PI serum levels
to quickly lead to a diagnosis. The ATS/ERS statement also recom-
mends genetic screening in a number of patient groups, including
adults with symptomatic emphysema and/or COPD and siblings of
individuals with diagnosed AATD.6 Testing should not be seen as a
ﬁnancial burden; the Alpha-1 Foundation provides a free conﬁ-
dential testing program9 and A1-PI manufacturers also offer free
AATD testing kits. AlphaNet, a not-for-proﬁt peer- and self-
management organization, provides a free disease management
program for individuals with AATD.10 Manufacturers support this
programwhich is available to all individuals diagnosed with AATD.
In addition, patient registries provide resources to patients (dis-
cussion forums, support groups) and actively contribute to the
development of programs aimed at improving diagnosis and
referral of AATD patients.11,12
A1-PI augmentation therapy is the only treatment targeting
the underlying cause of AATD-related emphysema
Administered intravenously at a weekly dose of 60 mg/kg body
weight, augmentation therapy raises serum A1-PI levels above the
threshold thought to be the minimum level that protects against
the risk of developing emphysema.13 The clinical efﬁcacy of
A1-PI augmentation therapy for AATD was suggested in two
small randomized clinical trials and recently conﬁrmed in the
largest placebo-controlled randomized clinical trial (RAPID,
NCT00261833) completed to date.14e16 The RAPID trial was
followed by the RAPID Extension trial (NCT00670007) in which
eligible patients, including those who had received placebo in
RAPID, received A1-PI augmentation therapy for two years.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of AATD and how to suspect, test and manage AATD individuals.6e8
Characteristics  Monogenic hereditary disorder
 Decreased levels or function of A1-PI
 Irreversible and progressive lung damage
 Can lead to emphysema and/or bronchiectasis
Common symptoms  Onset of symptoms in adults of any age
 Dyspnea on exertion, cough, wheezing, chronic
bronchitis, exacerbations
Suspecting AATD  Emphysema diagnosis
 COPD diagnosis
 Asthma diagnosis with incompletely reversible
airway obstruction and/or in individuals with late
onset of asthma-like symptoms
 Individuals with evidence of lung disease and smoking
or occupational exposure
 Unexplained liver disease
 Necrotizing panniculitis
 Siblings of individuals with diagnosed AATD
Testing  A1-PI blood levels
 Pi-typing (protein phenotyping)
 Genotyping
Disease management  Lifestyle modiﬁcations
 Pharmacological management of asthma and
COPD-like symptoms
 Usual management of liver disease
 A1-PI augmentation therapy in those with lung disease
A1-PI, alpha-1 proteinase inhibitor; AATD, alpha-1 antitrypsin deﬁciency; COPD,
chronic obstructive pulmonary disease.
Editorial / Heart & Lung 44 (2015) 463e464464An interim analysis showed a similar reduction in lung tissue
destruction in all patients during the RAPID Extension trial, irre-
spective of the treatment received in the RAPID trial. In those
patients who had received placebo during the RAPID trial, the lung
density lost during the initial two-year period was not regained.16
This ﬁnding demonstrates the disease-modifying effect of A1-PI
augmentation therapy in AATD patients and emphasizes the ad-
vantages of early diagnosis and treatment.
Targeted screening can enable early and appropriate
intervention, and improve long-term outcomes
AATD symptoms can be managed via the implementation of
lifestyle modiﬁcations such as smoking cessation, avoidance of
environmental risk factors, and pulmonary rehabilitation. In addi-
tion, medications indicated in the treatment of COPD/asthma (e.g.,
bronchodilators, corticosteroids, antibiotics, supplemental oxygen)
can also be given to alleviate respiratory symptoms. Early diagnosis
facilitates discussion and prompt implementation of treatment
options that will slow further deterioration and improve long-term
outcomes.6,16
Nurses are ideally placed to raise awareness of AATD diagnosis
and testing, and the availability of A1-PI augmentation
therapy
With the demonstrated efﬁcacy and safety of A1-PI augmenta-
tion therapy and the importance of lifestyle modiﬁcations in the
management of AATD-related emphysema, it is fundamentally
important to identify as early as possible individuals with AATD.
Diagnosis rates and times need to be improved as early interven-
tion is necessary to minimize disease progression and the
irreversible loss of lung tissue. The implementation of screeningalgorithms in the primary care setting is therefore warranted to
identify when asthma and COPD symptoms are due to AATD, and to
identify patients who may beneﬁt from treatment.
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